{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptId=17&max-date=2019-05-14", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?answeringDeptId=17&max-date=2019-05-14", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptId=17&max-date=2019-05-14&_metadata=all", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&answeringDeptId=17&max-date=2019-05-14", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptId=17&max-date=2019-05-14", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptId=17&max-date=2019-05-14", "items" : [{"_about" : "http://data.parliament.uk/resources/1126459", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1126459/answer", "answerText" : {"_value" : "
It is right that these decisions are clinically led. As for any other medical treatment, if two clinicians are of the opinion that, on balance, it is not in the best interest of the patient to prescribe a cannabis-based product, then it will not be prescribed.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"} } , "answeringMemberConstituency" : {"_value" : "South Ribble"} , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"} , "dateOfAnswer" : {"_value" : "2019-05-21", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-05-21T10:45:44.23Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-05-14", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what the process will be for patients that are refused a prescription for medical cannabis oil by their second opinion; and will he make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1528", "label" : {"_value" : "Biography information for Sir Mike Penning"} } , "tablingMemberConstituency" : {"_value" : "Hemel Hempstead"} , "tablingMemberPrinted" : [{"_value" : "Sir Mike Penning"} ], "uin" : "254164"} , {"_about" : "http://data.parliament.uk/resources/1126507", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1126507/answer", "answerText" : {"_value" : "
NHS Improvement has advised that the Trust responded to the hon. Member\u2019s letter of 14 March 2019 on 17 May 2019.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1585", "label" : {"_value" : "Biography information for Stephen Hammond"} } , "answeringMemberConstituency" : {"_value" : "Wimbledon"} , "answeringMemberPrinted" : {"_value" : "Stephen Hammond"} , "dateOfAnswer" : {"_value" : "2019-05-21", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-05-21T11:09:33.38Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-05-14", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Members: Correspondence"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether he holds information on when the hon. Member for West Lancashire will receive a response to correspondence sent to Lancashire Care Foundation Trust on 14 March 2018 on mental health care.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1538", "label" : {"_value" : "Biography information for Rosie Cooper"} } , "tablingMemberConstituency" : {"_value" : "West Lancashire"} , "tablingMemberPrinted" : [{"_value" : "Rosie Cooper"} ], "uin" : "254165"} , {"_about" : "http://data.parliament.uk/resources/1126508", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1126508/answer", "answerText" : {"_value" : "
The National Institute for Health and Care Excellence (NICE) and NHS England are leading the dialogue with Vertex Pharmaceuticals on access to their portfolio of cystic fibrosis medicines, including Orkambi and Symkevi.<\/p>
NHS England has proposed an offer that would represent the largest ever commitment of its kind in the history of the National Health Service - in the region of £500 million over five years - and would provide immediate access for patients to all Vertex licensed medicines in advance of assessment by NICE. The Government fully supports the approach that NICE and NHS England are adopting. It is crucial that patients have access to the most effective and innovative medicines at a price that represents value to the NHS.<\/p>
My Rt. hon. Friend the Secretary of State for Health and Social Care held a meeting on 11 March with all the parties to discuss how best to reach a deal so that people with cystic fibrosis and their families can benefit as soon as possible. Vertex, NICE and NHS England subsequently met on Thursday 21 March and have agreed to continue discussions.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"} } , "answeringMemberConstituency" : {"_value" : "South Ribble"} , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"} , "dateOfAnswer" : {"_value" : "2019-05-20", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-05-20T16:00:42.25Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-05-14", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Cystic Fibrosis: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what recent progress has been made on making (a) Orkambi and (b) Symkevi available on the NHS for people diagnosed with cystic fibrosis; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/253", "label" : {"_value" : "Biography information for Mr Laurence Robertson"} } , "tablingMemberConstituency" : {"_value" : "Tewkesbury"} , "tablingMemberPrinted" : [{"_value" : "Mr Laurence Robertson"} ], "uin" : "254113"} , {"_about" : "http://data.parliament.uk/resources/1126557", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1126557/answer", "answerText" : {"_value" : "
The number of employees in the Department from 1 April 2018 to 31 March 2019 who were absent due to mental health reasons, including stress was 46, this represented 3% of the total workforce. The proportion of sickness absence related to mental health reasons, including stress, was 22% of the overall sickness absence for the Department for the same time period.<\/p>
<\/p>
The estimated cost to the Department from 1 April 2018 to 31 March 2019 for employees taking sickness absence, is estimated at £936,927.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4008", "label" : {"_value" : "Biography information for Dame Caroline Dinenage"} } , "answeringMemberConstituency" : {"_value" : "Gosport"} , "answeringMemberPrinted" : {"_value" : "Caroline Dinenage"} , "dateOfAnswer" : {"_value" : "2019-05-22", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-05-22T10:28:23.41Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-05-14", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Department of Health and Social Care: Sick Leave"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, how many and what proportion of officials in his Department took sick leave for reasons relating to stress in the last 12 months; what proportion that leave was of total sick leave taken in his Department; and what the cost was to his Department of officials taking sick leave over that period.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/151", "label" : {"_value" : "Biography information for Tom Brake"} } , "tablingMemberConstituency" : {"_value" : "Carshalton and Wallington"} , "tablingMemberPrinted" : [{"_value" : "Tom Brake"} ], "uin" : "254066"} , {"_about" : "http://data.parliament.uk/resources/1126575", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1126575/answer", "answerText" : {"_value" : "
Health Education England (HEE) published the Cancer Workforce Plan for England in December 2017, which committed to the expansion of capacity and skills of the cancer workforce, including an ambition to attract and retain more cancer specialists, including histopathologists, by 2021. In 2019, 100% of specialist pathology training places, including histopathology, were filled.<\/p>
Following the publication of the NHS Long Term Plan in January 2019, HEE is now working with NHS England and NHS Improvement to understand the longer-term workforce implications for the further development of cancer services.<\/p>
Locally, responsibility for assessing and managing staffing levels, including specialty staff, rests with individual NHS trusts who are best placed to decide how many staff they need to provide a given service.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"} } , "answeringMemberConstituency" : {"_value" : "South Ribble"} , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"} , "dateOfAnswer" : {"_value" : "2019-05-22", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-05-22T10:38:44.277Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-05-14", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Pathology: Staff"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure the (a) recruitment and (b) retention of adequate levels of NHS staff in cancer pathology units.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4609", "label" : {"_value" : "Biography information for Eleanor Smith"} } , "tablingMemberConstituency" : {"_value" : "Wolverhampton South West"} , "tablingMemberPrinted" : [{"_value" : "Eleanor Smith"} ], "uin" : "254258"} , {"_about" : "http://data.parliament.uk/resources/1126597", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1126597/answer", "answerText" : {"_value" : "
Local clinical commissioning groups (CCGs), with their clinical expertise, are responsible for commissioning high-quality care to meet the needs of their populations. CCGs are required to carefully consider the National Institute for Health and Care Excellence guidelines in making commissioning decisions. These are available at the following link:<\/p>